ClinicalTrials.Veeva

Menu
D

DENT Neurologic Institute | Headache, Concussion, and Neuro-oncology Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Sumatriptan
Lamotrigine
Galcanezumab
ABP-450
LY3305677
Dexamethasone
LY3841136
Simufilam
ACP-204
Naprosyn

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 63 total trials
Locations recently updated

A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat...

Enrolling
Migraine
Medication Overuse Headache
Drug: Placebo
Drug: Eptinezumab

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo
Locations recently updated

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy...

Enrolling
Tremor
Parkinson Disease
Drug: Suvecaltamide
Drug: Placebo

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Aducanumab

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the...

Enrolling
RLS
Drug: Placebo
Drug: HORIZANT 300 mg

The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of R...

Enrolling
RLS
Drug: HORIZANT 600 mg

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Enrolling
Myasthenia Gravis, Generalized
Drug: Descartes-08

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo

This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine...

Invitation-only
Migraine
Drug: ABP-450

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per m...

Active, not recruiting
Migraine
Drug: ABP-450
Drug: Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling
Agitation
Alzheimer's Type Dementia
Drug: Masupirdine 100 mg
Drug: Masupirdine 50 mg

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only
Alzheimer Disease
Drug: Simufilam

Trial sponsors

Lilly logo
D
C
A
Allergan logo
A
Biogen logo
C
C
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems